Clinical trials · Illinois
Cancer clinical trials in Illinois
We’re tracking 679 recruiting cancer studies with a site in Illinois — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT07562152RecruitingPhase 3
Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
Arlington Heights, IllinoisAges 18 years+ - NCT07365995RecruitingPhase 3
New drug for advanced prostate cancer vs. standard chemo
This trial tests a new drug called BNT324 against the standard chemotherapy docetaxel for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the new treatment can help control the cancer better.
Niles, IllinoisAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Chicago, IllinoisAges 18 years+ - NCT06820463RecruitingPhase 2
Study of telisotuzumab adizutecan plus chemo for metastatic colorectal cancer
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Chicago, IllinoisAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Chicago, IllinoisAges 18 years+ - NCT07659782RecruitingPhase 2
Study of VS-7375 for KRAS G12D lung cancer
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
Chicago, IllinoisAges 18 years+ - NCT07149363RecruitingPhase 2
Chemo and immunotherapy after surgery for small cell lung cancer
This trial tests whether adding immunotherapy (durvalumab) to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. It is for people who have had their cancer completely removed and are well enough to start treatment soon after surgery.
Chicago, IllinoisAges 18 years+ - NCT07214779RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Chicago, IllinoisAges 18 years+ - NCT05983276RecruitingPhase 2
Combination therapy for drug-resistant ovarian cancer
This trial tests a new two-drug combination (decitabine and selinexor) given with standard chemotherapy to see if it can reverse drug resistance in ovarian cancer that has come back or worsened after treatment.
Maywood, IllinoisAges 18 years+ - NCT07128199RecruitingPhase 3
Zipalertinib after surgery for early-stage lung cancer with uncommon EGFR mutations
This study tests whether taking zipalertinib after lung cancer surgery can help prevent the cancer from coming back in people whose tumors have uncommon EGFR gene changes. It is a pill taken daily after recovery from surgery.
Chicago, IllinoisAges 18 years+ - NCT05797831RecruitingPhase 2/Phase 3
Maintenance treatment for TP53-wildtype endometrial cancer
This trial tests navtemadlin as a maintenance (ongoing) treatment to help prevent endometrial cancer from coming back after chemotherapy works. It is mainly for people whose cancer has certain genetic features (TP53 “wildtype”) and who had a strong response to first-line taxane–platinum chemo.
Hinsdale, IllinoisAges 18 years+ - NCT07717437Recruiting
Liver cancer registry for patients who had vein embolization
This registry collects medical images and health information from patients with liver cancer or liver metastases who had a procedure to block certain liver veins (PVE/HVE). The goal is to learn more about this technique and help future patients.
Chicago, IllinoisAges 18 years+ - NCT07680790RecruitingPhase 3
New drug combination for advanced egfr lung cancer
This study tests a new drug (izalontamab brengitecan) combined with a standard targeted therapy (osimertinib) compared to standard treatments alone for advanced EGFR-mutant non-small cell lung cancer. It aims to see if the combination works better.
Ottawa, IllinoisAges 18 years+ - NCT07680439RecruitingPhase 2
CAR T cell therapy study for children with DIPG brain tumor
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
Chicago, IllinoisAges 1–26 - NCT07647328RecruitingPhase 3
Camizestrant and ribociclib for advanced hormone-receptor-positive breast cancer
This trial tests a combination of two drugs (camizestrant and ribociclib) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. The study aims to see if this combination helps patients whose cancer cannot be surgically removed or treated with radiation alone.
Evanston, IllinoisAges 18–130 - NCT05671887Recruiting
Double lung transplant registry for certain lung-limited cancers
This study follows people who are getting a double lung transplant and have specific lung-only (or lung-limited) cancer or other serious lung conditions. It’s an observational registry, meaning it collects real-world information to learn which patients may benefit from transplant and how they do afterward.
Chicago, IllinoisAges 18–75 - NCT07621718RecruitingPhase 3
Zoldonrasib plus chemotherapy for metastatic pancreatic cancer with KRAS mutation
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
Chicago, IllinoisAges 18 years+ - NCT07621757Enrolling by invitation
Genetic Risk Testing for Colorectal Cancer Screening
This study looks at how genetic risk information can help decide who needs colorectal cancer screening and when. Researchers want to see if testing for genetic risk factors improves screening decisions for people who haven't had a colonoscopy before.
Evanston, IllinoisAges 45–75 - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
O'Fallon, IllinoisAges 18 years+ - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Zion, IllinoisAges 18 years+ - NCT07594626RecruitingPhase 1/Phase 2
BMS-986504 and Pemetrexed for Advanced Tumors With MTAP Loss
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
Chicago, IllinoisAges 18 years+ - NCT07566156RecruitingPhase 3
New drug combination vs. radiation for bladder cancer preservation
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
Hinsdale, IllinoisAges 18 years+ - NCT07556380Recruiting
Mobile app to help melanoma survivors stay safe in the sun
This study helps people who've had melanoma learn healthy habits around sun exposure and outdoor activity. You'll use a smartphone app, wear special tracking devices, and share information about your time outside to help researchers develop better ways to protect skin cancer survivors.
Chicago, IllinoisAges 18 years+ - NCT07553234Recruiting
Gut Health and Side Effects from Breast Cancer Hormone Treatment
This study looks at how the bacteria in your digestive system may affect side effects from abemaciclib, a hormone-based breast cancer drug. By collecting stool samples, researchers hope to understand which patients might experience fewer problems and how to better manage treatment.
Chicago, IllinoisAges 18 years+
Cancer trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting cancer studies listed above.
- Illinois Cancer Specialists · 3 studies
- NorthShore University HealthSystem-Evanston Hospital · 2 studies
- Northwestern University · 2 studies
- Research Site · 2 studies
- Rush University Medical Center · 2 studies
- University of Chicago Medical Center · 2 studies
- Ann & Robert H. Lurie Children's Hospital of Chicago
- Carle Cancer Center
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in Illinois?
- Yes. We're currently tracking 679 recruiting cancer studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.